Pyxis Oncology Inc (PYXS) Stock Analysis
Verdict: AVOID
Imminent cash depletion and clinical trial binary risks overshadow pipeline potential, forcing high dilution probability before clinical inflection.
Investment score: 34/100
Analysis as of
Is Pyxis Oncology Inc stock worth reviewing? The TradeMates thesis
The model rates PYXS as AVOID due to severe cash burn (-$63.5M FCF) against limited cash reserves ($15.42M), making significant equity dilution virtually unavoidable before late-stage pipeline commercialization.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Pyxis Oncology Inc opportunities and risks
What speaks for PYXS
- Early clinical promise in ADC pipeline (PYX-201 and PYX-202)
What speaks against PYXS
- Severe liquidity depletion and imminent equity dilution hazard
Peers and competitors
- PRTC.L
- IMRX
- CYDY
- ANIK
- NWBO
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PYXS | n/a | 19.3x | n/a | 99.8% | -803.8% | -31.9% |
| IMRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -35.3% |
| CYDY | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.3% |
| ANIK | n/a | 2.3x | 98.2x | 62.2% | -3.1% | 0.2% |
| NWBO | n/a | 124.9x | n/a | -39.0% | -1736.4% | -17.8% |
| Peer median | n/a | 1.2x | n/a | 0.0% | -1.6% | -12.1% |
Frequently asked questions about Pyxis Oncology Inc (PYXS)
Is PYXS stock a good investment?
The TradeMates model rates Pyxis Oncology Inc as AVOID with an investment score of 34/100. The model rates PYXS as AVOID due to severe cash burn (-$63.5M FCF) against limited cash reserves ($15.42M), making significant equity dilution virtually unavoidable before late-stage pipeline commercialization. This is algorithmic model output, not personal investment advice.
Is PYXS stock a buy?
The TradeMates model verdict for PYXS is AVOID with an investment score of 34/100. Treat this as a model signal to review, not a personal buy recommendation.